Loading...
•
Mar 31, 2022
Aurinia Q1 2022 Earnings Report
Reported first quarter financial results, showing net revenue of $21.6 million and maintaining revenue guidance for 2022.
Key Takeaways
Aurinia Pharmaceuticals reported net revenue of $21.6 million for Q1 2022, a significant increase compared to the prior year period. The company maintains its net revenue guidance of $115 million to $135 million for 2022.
Net product revenues were $21.6 million for the quarter ended March 31, 2022, compared to $914 thousand in the prior year period.
Aurinia added 461 patient start forms (PSFs) during the first quarter 2022, as compared to 257 in the first quarter 2021.
PSF conversion rates are now at 80% after 90 days; confirmed patient access to LUPKYNIS through payors and plans remains steady representing about 90% of U.S. total lives.
Regulatory review of the European Medicines Agency (EMA) marketing authorization application (MAA) remains on track with a European Commission (EC) approval decision expected in second half of 2022.
Forward Guidance
Aurinia maintains its net revenue guidance of $115 million to $135 million from sales of LUPKYNIS for 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...